Moreover, this treatment normalized the HFD-induced NASH and improved liver inflammation, also reducing TNFα mRNA expression and circulating TNFα [24], a key cytokine involved in the progression from NAFLD to NASH. The gene discussed is TNF; the disease is metabolic dysfunction-associated steatotic liver disease.